Pages

▼
Monday, December 12, 2011

2011 Exit/Financing of the Year Nominee: Eisai/SFJ Pharma

›
It's time for the IN VIVO Blog's Fourth Annual Deal of the Year! competition. This year we're once again presenting awards in th...

2011 M&A of the Year Nominee: Abbott/Abbott Pharma

›
It's time for the IN VIVO Blog's Fourth Annual Deal of the Year! competition. This year we're once again presenting awards in th...
Friday, December 09, 2011

2011 M&A Of the Year Nominee: Takeda/Nycomed

›
It's time for the IN VIVO Blog's Fourth Annual Deal of the Year! competition. This year we're once again presenting awards in th...

Deals of the Week Ponders 13 Ways Of Looking At A Mockingbird

›
Like mockingbirds, biosimilars are emerging as some of the pharma industry's best mimics, but are different indeed from their patented...
1 comment:
Thursday, December 08, 2011

Financings of the Fortnight Ponders The Twilight of the Eurozone

›
Three years past the downfall of Lehman Brothers, the defining seismic event of the U.S.-led recession, life-science venture capitalists ...
Wednesday, December 07, 2011

Exit/Financing of the Year Nominee: Radius Pharma

›
It's time for the IN VIVO Blog's Fourth Annual Deal of the Year! competition. This year we're once again presenting awards in th...

2011 Alliance of the Year Nominee: Pfizer/Puma

›
It's time for the IN VIVO Blog's Fourth Annual Deal of the Year! competition. This year we're once again presenting awards in th...

2011 Alliance Of the Year Nominee: Pfizer's CTIs

›
It's time for the IN VIVO Blog's Fourth Annual Deal of the Year! competition. This year we're once again presenting awards in th...
1 comment:
Tuesday, December 06, 2011

2011 M&A of the Year Nominee: Endo/AMS

›
It's time for the IN VIVO Blog's Fourth Annual Deal of the Year! competition. This year we're presenting awards in three categor...
Friday, December 02, 2011

Deals of the Week Checks on Gilead/Pharmasset Ripples

›
The $11 billion Gilead Sciences paid for Pharmasset and its promising Phase II nucleoside polymerase inhibitor on Nov. 21 opened eyes, b...